Brokerages Set Microbot Medical Inc. (NASDAQ:MBOT) Price Target at $7.50

Microbot Medical Inc. (NASDAQ:MBOT) has been assigned an average rating of “Moderate Buy” from the five brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $7.50.

Several analysts have recently weighed in on MBOT shares. B. Riley Financial assumed coverage on shares of Microbot Medical in a research note on Tuesday, February 10th. They issued a “buy” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Microbot Medical in a report on Friday, November 28th. Finally, Roth Mkm began coverage on Microbot Medical in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $5.50 price objective for the company.

Institutional Trading of Microbot Medical

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Beacon Capital Management LLC raised its holdings in Microbot Medical by 37.5% in the 3rd quarter. Beacon Capital Management LLC now owns 22,000 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 6,000 shares during the period. Cetera Investment Advisers boosted its stake in Microbot Medical by 38.8% during the fourth quarter. Cetera Investment Advisers now owns 29,313 shares of the biotechnology company’s stock worth $59,000 after buying an additional 8,201 shares during the period. Cornerstone Advisory LLC acquired a new stake in shares of Microbot Medical during the third quarter valued at about $30,000. Zacks Investment Management acquired a new stake in shares of Microbot Medical during the third quarter valued at about $33,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Microbot Medical in the 3rd quarter valued at approximately $37,000. 16.30% of the stock is owned by institutional investors and hedge funds.

Microbot Medical Trading Up 2.9%

Shares of MBOT stock opened at $2.45 on Friday. Microbot Medical has a twelve month low of $1.34 and a twelve month high of $4.67. The company’s 50-day moving average price is $2.11 and its 200-day moving average price is $2.52. The stock has a market cap of $164.54 million, a price-to-earnings ratio of -5.44 and a beta of 1.22.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.